Bio-Techne Corporation announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne's Lunaphore branded end-to-end spatial biology offering, including its complete range of instruments (COMET) and kits that offer high-value solutions for the translational research community. COMET, a best-in-class spatial biology platform, seamlessly integrates into standard clinical research workflows.

Using off-the-shelf, clinically IHC-validated antibodies, new panels can be quickly developed and validated. Additionally, COMET enables high-plex workflow automation, adding unique value to clinical studies by facilitating robust and timely decision-making in treatment strategies. Research conducted in collaboration with Prof. Paolo Ascierto, National Tumor Institute Fondazione G. Pascale, and leading AI-powered spatial biomarker and diagnostics company, Nucleai, uncovered potential tumor microenvironment (TME) features predictive of response to therapy.

In the cohort study of immunotherapy-treated metastatic melanoma patients, a comprehensive spatial immuno-oncology multiplex immunofluorescence (mIF) panel was combined for the first time with advanced AI-powered biomarker analysis. The findings highlight that the fully- automated workflow and AI tissue analytics can be applied more broadly in immunotherapy drug development to enhance the understanding of treatment efficacy, ultimately improving patient outcomes. Another study conducted in collaboration with Prof. Janis Taube, Johns Hopkins University School of Medicine, demonstrates the potential of the novel amplification technique on the COMET platform, allowing scientists to comprehensive profile the TME, leading the way for improved insights in clinical research.

At this year's Society for Immunotherapy of Cancer's (SITC) Annual Meeting novel data sets will be presented, showcasing the scientific advancements brought by COMET.